Triptolide (Synonyms: NSC 163062, PG 490) |
|
Catalog No.GC14402
|
Triptolide is a diterpene triepoxide isolated for the first time from the medicinal plant Tripterygium wilfordii, exhibiting immunosuppressive, anti-inflammatory, anti-proliferative, and antitumor effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 38748-32-2
Sample solution is provided at 25 µL, 10mM.
Triptolide is a diterpene triepoxide isolated for the first time from the medicinal plant Tripterygium wilfordii, exhibiting immunosuppressive, anti-inflammatory, anti-proliferative, and antitumor effects. It acts as an inhibitor of NF-κB activation, where NF-κB is a family of transcription factor protein complexes[1]. Triptolide possesses broad-spectrum anticancer activity, inhibiting the development of colon cancer, breast cancer, renal cell carcinoma, and cervical cancer[2].
In vitro, triptolide (50 nM, 72 h) significantly inhibits the proliferation of ovarian cancer cells SKOV3 and A2780. Triptolide (15 nM, 48h) significantly inhibits cell migration and blocks the invasive capability of cells[2]. Triptolide (50-200 nmol/L) incubated with PANC-1 and MiaPaCa-2 cells significantly reduces cell viability without affecting the viability of normal pancreatic ductal cells[3]. The IC50 value of triptolide on RSF cell viability is 74.3 nM, and its IC50 value on RSF cell proliferation is 20.4 nM[4]. Triptolide (0-150 nM) significantly inhibits the viability of HK1, FaDu, and C666-1 cells in a dose- and time-dependent manner[5].
In vivo, treatment with triptolide (1 mg/kg/d, p.o.) for three weeks in nude mice reduced the number of metastatic nodules by approximately 80%[2]. Triptolide (0.2 mg/kg/d) administered to mice with transplanted pancreatic tumors for 60 days reduced pancreatic cancer growth and significantly decreased local tumor spread[3].
References:
[1] Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12).
[2] Zhao H, Yang Z, Wang X, et al. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin[J]. Experimental & molecular medicine, 2012, 44(11): 633-641.
[3] Phillips P A , Dudeja V , Mccarroll J A ,et al.Triptolide Induces Pancreatic Cancer Cell Death via Inhibition of Heat Shock Protein 70[J].Cancer Research, 2007, 67(19):9407.
[4] Kusunoki N, Yamazaki R, Kitasato H, Beppu M, Aoki H, Kawai S: Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts. BMC Pharmacol 2004, 4:2.
[5] Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190. Published 2021 Jun 9.
| Cell experiment [1]: | |
|
Cell lines |
SKOV3 and A2780 cells |
|
Preparation Method |
SKOV3 and A2780 cells were plated in 96-well plates (5 × 103/well). 24h later, triptolide was added to a final concentration of 0, 1.5, 5, 15, 50, or 150 nM for 72 h. |
|
Reaction Conditions |
0, 1.5, 5, 15, 50, or 150 nM; 72 h |
|
Applications |
Triptolide (50nM, 72 h) noticeably inhibited ovarian cancer cell proliferation. Triptolide (15nM) significantly inhibited cell migration 48h after wounding. Triptolide (15nM) markedly blocked the invasive capacity of SKOV3 and A2780 cells. |
| Animal experiment [2]: | |
|
Animal models |
orthotopic mouse model |
|
Preparation Method |
Mice were then randomized into two treatment groups: (a) control and (b) triptolide-treated mice. Mice were given daily i.p. injections of triptolide (0.2 mg/kg) or vehicle (DMSO) for 60 days. |
|
Dosage form |
0.2 mg/kg/d; 60 days; i.p. |
|
Applications |
After a daily injection of triptolide (0.2 mg/kg) for 60 days, the tumor volume was significantly reduced. triptolide also significantly reduced the incidence of local-regional tumor spread. |
|
References: [1] Zhao H, Yang Z, Wang X, et al. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin[J]. Experimental & molecular medicine, 2012, 44(11): 633-641. |
|
| Cas No. | 38748-32-2 | SDF | |
| Synonyms | NSC 163062, PG 490 | ||
| Chemical Name | (6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2H)-one | ||
| Canonical SMILES | CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C | ||
| Formula | C20H24O6 | M.Wt | 360.41 |
| Solubility | ≥ 36 mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7746 mL | 13.8731 mL | 27.7462 mL |
| 5 mM | 554.9 μL | 2.7746 mL | 5.5492 mL |
| 10 mM | 277.5 μL | 1.3873 mL | 2.7746 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















